Inventor
PATUREL CARINE
FR25 patents
⚠️ This page may combine multiple inventors who share the name “PATUREL CARINE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INNATE PHARMA
21 patentsUS10577419B2Mar 3, 2020
KIR3DL2 binding agents
INNATE PHARMA15 citations90
US10711063B2Jul 14, 2020
Neutralization of inhibitory pathways in lymphocytes
INNATE PHARMA8 citations83
US10246510B2Apr 2, 2019
KIR3DL2 binding agents
INNATE PHARMA9 citations83
US10676523B2Jun 9, 2020
Treatment regimens using anti-NKG2A antibodies
INNATE PHARMA7 citations80
US11958907B2Apr 16, 2024
CD73 blockade
INNATE PHARMA4 citations73
US11572410B2Feb 7, 2023
Neutralization of inhibitory pathways in lymphocytes
INNATE PHARMA3 citations72
US10766966B2Sep 8, 2020
CD73 blockade
INNATE PHARMA5 citations72
US11130817B2Sep 28, 2021
CD73 blocking agents
INNATE PHARMA3 citations71
US11377503B2Jul 5, 2022
Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
INNATE PHARMA3 citations70
US11858990B2Jan 2, 2024
KIR3DL2 binding agents
INNATE PHARMA2 citations69
US10870700B2Dec 22, 2020
Neutralization of inhibitory pathways in lymphocytes
INNATE PHARMA6 citations69
US10736963B2Aug 11, 2020
Methods for detecting tissue infiltrating NK cells
INNATE PHARMA2 citations67
US12365731B2Jul 22, 2025
NKp46 binding agents
INNATE PHARMA0 citations62
US11377492B2Jul 5, 2022
NKp46 binding agents
INNATE PHARMA1 citations62
US12528876B2Jan 20, 2026
CD73 blocking antibodies
INNATE PHARMA0 citations61
US12202907B2Jan 21, 2025
Nucleic acids encoding and methods of producing proteins comprising antibody chains
INNATE PHARMA0 citations59
US12037392B2Jul 16, 2024
Treatment regimens using anti-NKG2A antibodies
INNATE PHARMA0 citations59
US11578136B2Feb 14, 2023
Compositions and methods for treating cancer
INNATE PHARMA1 citations59
US12448442B2Oct 21, 2025
Treatment of T cell lymphoma
INNATE PHARMA0 citations52
US9944712B2Apr 17, 2018
TLR3 binding agents
INNATE PHARMA0 citations49
US11970535B2Apr 30, 2024
Treatment with anti-KIR3DL2 agents
INNATE PHARMA0 citations48